Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2024-05-27 Regulatory Filings
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences AG gibt strategischen Zusammenschluss zwischen palleos healthcare GmbH und OCT Clinical GmbH bekannt
Regulatory Filings Classification · 1% confidence The document is a press release from Xlife Sciences AG announcing a strategic merger between two of its portfolio companies, palleos healthcare GmbH and OCT Clinical GmbH. It details the business rationale, management commentary, and market context for the merger. This type of announcement, which details corporate actions like mergers and acquisitions (M&A) or significant strategic partnerships, falls under the 'M&A Activity' category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), as it specifically concerns a transaction (merger/takeover proposal context).
2024-05-27 German
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report
Earnings Release Classification · 1% confidence The document is an 'Ad-hoc' announcement dated April 30, 2024, titled "Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report". It explicitly states that the company 'released the 2023 Valuation Report today' and provides key summary figures from that report (valuation range, sector contributions). Crucially, the document concludes by stating: 'The complete 2023 Valuation Report from Xlife Sciences is available for download at [link] in the «Financial Reports» section.' Since the text is short (3465 chars) and functions primarily to announce the availability of the detailed 'Valuation Report' rather than being the report itself, it fits the definition of a Report Publication Announcement (RPA). It is not a standard 10-K, IR, or ER. FY 2023
2024-04-30 English
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report
Earnings Release Classification · 1% confidence The document is an 'Ad hoc announcement' released on April 30, 2024, titled 'Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report'. It explicitly states that the '2023 Valuation Report' is being released and provides key highlights and a link for download. Since the document itself is short (3283 chars) and primarily serves to announce the availability of a detailed report (the 'Valuation Report'), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive report itself (like 10-K or IR). The content is an announcement about the publication of a valuation report, not the full report or an earnings release. FY 2023
2024-04-30 English
Xlife Sciences AG meldet starkes Portfolio-Wachstum und strategische Fortschritte im Valuation Report 2023
Regulatory Filings Classification · 1% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and explicitly states: 'Xlife Sciences AG meldet starkes Portfolio-Wachstum und strategische Fortschritte im Valuation Report 2023' and 'Xlife Sciences AG (SIX: XLS) veröffentlichte heute den Valuation Report 2023...'. It is a short announcement (under 5000 characters) whose primary purpose is to inform the market that the 'Valuation Report 2023' has been published and provides a link to download the full report. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA). While the content relates to a valuation report, the document itself functions as the announcement of that report's release, not the comprehensive report itself.
2024-04-30 German
Xlife Sciences AG Publishes 2023 Annual Report
Report Publication Announcement Classification · 1% confidence The document is titled "Xlife Sciences AG Publishes 2023 Annual Report" and contains key financial highlights for the year 2023, including revenues, EPS, and balance sheet figures. It explicitly mentions that the "complete 2023 annual report, including the consolidated financial statements... were also published today". However, the document itself is a press release summarizing the results and announcing the availability of the full report. According to Rule 2 (The "MENU VS MEAL" Rule), if a document is short and announces that the full report is attached or available for download, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement summarizing the 2023 results and directing the user to the full report, RPA is the most appropriate classification, rather than 10-K (which would be the full report itself).
2024-04-23 English
Xlife Sciences AG Publishes 2023 Annual Report
Earnings Release Classification · 1% confidence The document is titled "Xlife Sciences AG Publishes 2023 Annual Report" and provides a summary of the financial and operational results for the full year 2023, including key financial highlights (revenues, EPS, balance sheet totals) and operational progress. It explicitly states that the "complete 2023 annual report, including the consolidated financial statements... were also published today." Although it summarizes the annual results, the primary function of this specific text, which is released as an 'Ad hoc announcement pursuant to Art. 53 LR', is to announce the availability of the full Annual Report. However, the content provided is substantial, covering key financial highlights and management commentary, which strongly aligns with an Earnings Release (ER) or a summary preceding the full 10-K/Annual Report. Given the context of Swiss regulatory announcements (Art. 53 LR) often summarizing the key findings of the annual filing, and the explicit mention of the full report being published elsewhere, this functions as the initial public disclosure of the annual results. Since the document contains detailed financial highlights for the full year (2023) and is not just a brief notice of publication, it fits best as an Earnings Release (ER) summarizing the annual performance, rather than just a Report Publication Announcement (RPA). If the text were much shorter and only pointed to the report, RPA would be appropriate. Since it contains the core numbers, ER is the better fit for the summary provided. FY 2023
2024-04-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.